title: Octreotide therapy in asparaginase-associated pancreatitis in childhood acute lymphoblastic leukemia.
abstract: Little is known about octreotide therapy in asparaginase-associated pancreatitis (AAP) in children. Of the 59 children with acute lymphoblastic leukemia (ALL) receiving E. coli L-asparaginase, 5 patients (8.5%) developed AAP. Octreotide was administered to four patients. Clinical and laboratory improvement were evident after octreotide therapy. There were no deaths and no severe adverse side effects were noted. No pseudocysts were detected; however, two of the four patients developed diabetes. One child without octreotide treatment developed chronic pancreatitis and pseudocyst. We conclude that octreotide therapy appears to be safe and potentially beneficial in the management of AAP in children.
authors: Division of Pediatric Gastroenterology, China Medical University Hospital, Taichung, Taiwan.
authors: Shu-Fen
authors: SF
authors: Wu
authors: An-Chyi
authors: AC
authors: Chen
authors: Ching-Tien
authors: CT
authors: Peng
authors: Kang-Hsi
authors: KH
authors: Wu
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001215:Asparaginase / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D015282:Octreotide / Q000627:therapeutic use*; D010195:Pancreatitis / Q000139:chemically induced / Q000188:drug therapy*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D005765:Gastrointestinal Agents; D001215:Asparaginase; D015282:Octreotide